| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
James Mulay is Director at FLGT and has filed Form 4s across 2 companies. James Mulay's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $155K at current prices.
Historically, James Mulay's trades have earned a below-average insider score of 35/100 across 10 rated trades. Over a 12-month horizon, none of those trades were profitable, with an average 12-month return of -83.2%.
The biggest single holding is FLGT (~$155K) as Director.
James Mulay has 15 Form 4 filings on record from October 2016 to July 2026, across 2 companies: Director at CG Oncology (CGON), 2024–2026; Director at Fulgent Genetics (FLGT), 2016–2019.
The 35 reported transactions were 16 open-market sales, 13 option exercises, 5 option or other derivative awards and 1 stock award.
Counted by filing, the open-market trades come to no purchases and 9 sales worth about $6.3M.
The largest open-market sale was 24,165 shares of CGON at an average $75.16 on July 10, 2026, about $1.8M.
All 9 sales since April 2023 were made under a Rule 10b5-1 trading plan, set up in advance.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jul 10, 2026 | CGON Cg Oncology, Inc. | Director | Sale+OE10b5-1 | 24,165 | $75.16 | $1,816,241.40 | - | -15.9% | - | |
| Jun 15, 2026 | CGON Cg Oncology, Inc. | Director | Sale+OE10b5-1 | 1,964 | $60.12 | $118,075.68 | - | +23.9% | - | |
| Apr 17, 2026 | CGON Cg Oncology, Inc. | Director | Sale+OE10b5-1 | 15,600 | $73.01 | $1,138,956.00 | - | -5.4% | - | |
| Mar 16, 2026 | CGON Cg Oncology, Inc. | Director | Sale+OE10b5-1 | 1,964 | $63.50 | $124,714.00 | - | -9.6% | - | |
| Jan 9, 2026 | CGON Cg Oncology, Inc. | Director | Sale+OE10b5-1 | 11,145 | $52.47 | $584,798.73 | - | +26.5% | - | |
| Oct 9, 2025 | CGON Cg Oncology, Inc. | Director | Sale+OE10b5-1 | 5,903 | $43.99 | $259,672.97 | - | -4.5% | +43.5% | |
| Sep 29, 2025 | CGON Cg Oncology, Inc. | Director | Sale+OE10b5-1 | 12,755 | $39.19 | $499,868.45 | - | +2.0% | +80.5% | |
| Sep 19, 2025 | CGON Cg Oncology, Inc. | Director | Sale+OE10b5-1 | 22,686 | $39.01 | $884,909.38 | - | +3.0% | +102.2% | |
| Sep 5, 2025 | CGON Cg Oncology, Inc. | Director | Sale+OE10b5-1 | 27,015 | $31.53 | $851,797.10 | - | +35.3% | +125.8% |